Company intelligence / Profile preview
Shanghai Sunway Biotech
Shanghai, Shanghai, China
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
The company has received approval for oncolytic virus therapy for cancer treatment in China. Their first product, Gendicine (recombinant p53 gene), was approved in China in 2004 for head and neck cancer, and Oncorine (E1B/E3 deficient adenovirus) was approved in 2005.
- Therapeutic areas
- OncologyCardiovascularHematology
- Modalities
- Oncolytic virusBiosimilarColony-stimulating factorsGene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
The Johns Hopkins UniversityTechpool Bio-Pharma
Beyond the preview
Go deeper on Shanghai Sunway Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Sunway Biotech.